<DOC>
	<DOCNO>NCT01259193</DOCNO>
	<brief_summary>Sorafenib , oral multikinase inhibitor target several tyrosine-kinase receptor antiangiogenesis antiproliferation HCC , first approve target therapy HCC . Zoledronic acid use treatment bone metastasis diverse malignant cancer . Emerging data suggest zoledronic acid may also exhibit anticancer property . The objective study evaluate safety Sorafenib combine Zoledronic Acid evaluate overall survival time progression .</brief_summary>
	<brief_title>Clinical Study Sorafenib Zoledronic Acid Treat Advanced HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Age ≥ 18 year Hepatocellular carcinoma confirm pathology identify radiological image typical feature patient unresectable primary hepatocellular carcinoma ChildPugh Class A B , score ≤ 7 ECOG score 02 Expected survival time le 12 week At least one tumor nodule one unidimension ≥ 1 cm Peripheral platelet 50×10 ( 9 ) /L Peripheral hemoglobin 85g/L Peripheral albumen 28g/L Total bilirubin ≤3.0mg/dl ALT AST ≤ 5.0 x upper limit normal Serum amylase ≤ 1.5x upper limit normal Serum creatinine ≤ 1.5x upper limit normal PTINR &lt; 2.3 PT prolong 4 normal Congestive heart failure &gt; NYHA class 2 History active coronary disease ( except myocardial infarction 6 month ago ) Receive antiarrhythmia treatment ( except βreceptor blocker , calcium channel blocker digoxin ) uncontrollable hypertension Active clinically serious infection ( &gt; 2 NCICTC Version 3.0 ) History HIV infection Inclined hemorrhage active hemorrhage 1 month Substance abuse , medical , psychological social condition may interfere patient 's participation study Pregnant breastfeeding.Women childbearing potential must negative pregnancy test perform within 7 day prior enrol portion study Known suspect allergy agent give association trial Concomitant anticancer therapy ( except immunotherapy Chinese traditional treatment ) Surgical operation within 4 week prior enrol portion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Zoledronic Acid</keyword>
	<keyword>toxic reaction</keyword>
</DOC>